Sugi Predict

Sugi Predict / Compounds / SCHEMBL2690892

SCHEMBL2690892

SCHEMBL2690892

COC(=O)c1cc(N)c(I)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.50
▸ ALDH1A1 P00352 6/20 0.50
▸ GAA P10253 6/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ CFTR P13569 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ GLA P06280 2/20 0.50
▸ CASP1 P29466 1/20 0.50
▸ CASP7 P55210 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ NQO2 P16083 1/20 0.50
▸ ABL1 P00519 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ POLB P06746 1/20 0.40
▸ PDGFRB P09619 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ FLT1 P17948 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29790105 1.00 KDM4E (0.50) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL3970865 0.93 CFTR (0.54) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL24413993 0.87 CFTR (0.58) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL1720999 0.85 KDM4E (0.56) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL30280995 0.83 KDM4E (0.55) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL2318882 0.83 KDM4E (0.55) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL2897750 0.83 KDM4E (0.61) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL3974563 0.82 GAA (0.54) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL23874532 0.81 GAA (0.61) KDM4EALDH1A1GAAHSD17B10CFTR
SCHEMBL31515143 0.81 GAA (0.53) KDM4EALDH1A1GAAHSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286428-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-29 — — US disclosed
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 — — US disclosed
CN-114423757-B Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2024-07-02 — — CN disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 — — EP disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 — — EP disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed
CN-113717091-B Indole derivatives and preparation method and application thereof 南京医科大学 2023-03-10 — — CN disclosed
US-20220259205-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2022-08-18 — — US disclosed
EP-3999508-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS Bristol-Myers Squibb Company (US) 2022-05-25 — — EP disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 — — US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 — — US disclosed
EP-2259678-A1 PROTEIN KINASE MODULATORS Cylene Pharmaceuticals, Inc. (US) 2010-12-15 — — EP disclosed
US-7601750-B2 Small molecule inhibition of a PDZ-domain interaction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-10-13 — — US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 — — US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 — — US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 — — US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 — — WO disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 — — WO disclosed
US-20080021082-A1 Small molecule inhibition of a PDZ-domain interaction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021082-A1 Small molecule inhibition of a PDZ-domain interaction DVL1, DVL3, PDLIM5 KDM4E 2656/4885ALDH1A1 4535/4885GAA 4322/4885
US-20220259205-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS IRAK4, IRAK1, IRAK3 KDM4E 158/4885ALDH1A1 3949/4885GAA 4206/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 KDM4E 736/4885ALDH1A1 3801/4885GAA 1742/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD KDM4E 2811/4885ALDH1A1 2460/4885GAA 504/4885
US-12286428-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors IRAK4, IRAK1, IRAK3 KDM4E 158/4885ALDH1A1 3949/4885GAA 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.